MAPK9抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using MAPK9 mouse mAb against HEK293 (1) and U251 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using MAPK9 mouse mAb (green) and negative control (red).    

  
  

The MAPK9 antibody targets the Mitogen-Activated Protein Kinase 9 (MAPK9), also known as c-Jun N-terminal kinase 2 (JNK2), a member of the serine/threonine kinase family. MAPK9 is part of the JNK signaling pathway, which responds to extracellular stimuli such as cytokines, stress signals (e.g., UV radiation, osmotic shock), and growth factors. It regulates diverse cellular processes, including apoptosis, differentiation, proliferation, and inflammation. Upon activation via phosphorylation by upstream kinases (MAP2Ks), MAPK9 translocates to the nucleus, where it phosphorylates transcription factors like c-Jun, ATF2. and p53. modulating gene expression. Dysregulation of MAPK9 is implicated in diseases such as cancer, neurodegenerative disorders, and inflammatory conditions.

MAPK9 antibodies are critical tools for detecting and quantifying MAPK9 protein levels, phosphorylation status, and subcellular localization in research. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Antibodies may vary in clonality (monoclonal/polyoclonal), species reactivity (human, mouse, rat), and specificity (phospho-specific vs. total protein). Validating antibody specificity is essential to avoid cross-reactivity with closely related isoforms (e.g., JNK1 or JNK3). Applications include studying stress response pathways, disease mechanisms, and evaluating therapeutic agents targeting JNK signaling. Commercial MAPK9 antibodies often cite peer-reviewed data to ensure reproducibility in experimental models, from cell lines to tissue samples.